1. Academic Validation
  2. Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist

Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist

  • Neuroreport. 2002 Nov 15;13(16):2071-4. doi: 10.1097/00001756-200211150-00016.
Silvia Zucchini 1 Andrea Buzzi Marco Bergamaschi Claudio Pietra Gino Villetti Michele Simonato
Affiliations

Affiliation

  • 1 Department of Clinical and Experimental Medicine, Section of Pharmacology Neuroscience Center, University of Ferrara, via Fossato di Mortara, 17-19, 44100 Ferrara, Italy.
Abstract

The aim of this study was to evaluate the neuroprotective effect of CHF3381, a novel putative NMDA antagonist characterized by a good therapeutic index. We have compared the effects of CHF3381 on kainate seizure-induced neurodegeneration with those produced by the non competitive NMDA Receptor Antagonist MK-801 and by the Na channel blocker lamotrigine. All compounds have been employed at doses incapable of preventing or attenuating seizures. The fluorescent marker Fluoro-Jade B has been used to identify degenerating cells. Animals pretreated with lamotrigine presented the same degree of cell damage as the controls. As for the controls, a clear correlation was also observed between seizure severity and neurodegeneration. In contrast, MK-801 and CHF3381 completely prevented cell damage. These data indicate that CHF3381 may be successfully utilized in neurological disorders characterized by or associated with neurodegenerative excitotoxicity.

Figures
Products